InvestorsHub Logo
Followers 227
Posts 13150
Boards Moderated 0
Alias Born 09/26/2011

Re: None

Tuesday, 10/04/2016 8:37:18 AM

Tuesday, October 04, 2016 8:37:18 AM

Post# of 185

"Under the terms of the agreement, Summit will receive an upfront payment of $40M, up to $522M in milestones and escalating low-to-high-teens royalties on net sales. Sarepta and Summit will share utrophin modulator-related R&D costs on a 45%/55% basis starting in 2018. If Sarepta exercises its option on Latin America, Summit will be eligible for additional fees, milestones and royalties."


http://seekingalpha.com/news/3212206-sarepta-inks-deal-summit-therapeutics-duchenne-pipeline-candidates-summit-49-percent
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SMMT News